Lucy Therapeutics
Innovative biotech targeting mitochondrial dysfunction to combat CNS disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $12.5m | Early VC | |
| Total Funding | 000k | ||
Related Content
Lucy Therapeutics is a biotechnology company focused on addressing central nervous system (CNS) disorders by targeting mitochondrial dysfunction. The company operates in the healthcare and biotech market, serving clients such as pharmaceutical companies, research institutions, and healthcare providers. Lucy Therapeutics employs a research-driven business model, leveraging scientific discoveries to develop therapeutic solutions. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. By unraveling the complex processes that drive mitochondrial dysfunction, Lucy Therapeutics aims to slow or stop disease progression and restore health.
Keywords: biotechnology, CNS disorders, mitochondrial dysfunction, healthcare, research-driven, therapeutic solutions, pharmaceutical partnerships, licensing agreements, disease progression, health restoration.